Senti Biosciences Inc (SNTI)
Drugs • Health Care
July 15, 2026 Senti Biosciences Inc. Announces Strategic Transaction to Enhance Focus on Controllable Genetic Medicines Senti Biosciences has announced a strategic transaction to enhance its focus on controllable genetic medicines, transitioning its pipeline to a new entity. This move aims to advance promising therapies like SENTI-202 for AML, highlighting the potential of their innovative Regulator Dial™ technology.
May 14, 2026 Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and SENTI-202 Program Advancement Senti Biosciences Holdings reported its Q1 2026 financial results and significant developments in its SENTI-202 program targeting hematologic malignancies. The company secured a $40 million financing agreement, reduced operational costs, and improved its cash position, setting the stage for upcoming clinical trials.
May 14, 2026 Senti Biosciences Inc. Announces Significant Progress in AML Treatment Development Senti Biosciences has made significant strides in AML treatment with its investigational therapy SENTI-202, following a successful FDA RMAT meeting. The upcoming pivotal trial aims to evaluate the therapy's effectiveness using donor-derived cells, promising better outcomes for relapsed/refractory AML patients.
April 13, 2026 Senti Biosciences Set to Showcase Logic-Gated Cell Therapies at AACR Annual Meeting 2026 Senti Biosciences will present its innovative Logic-Gated cell therapies at the AACR Annual Meeting 2026. CEO Timothy Lu will discuss engineered NK cells and promising clinical trial results, highlighting advancements in cancer treatment.
April 01, 2026 Senti Biosciences Inc. Unveils Groundbreaking CAR Design in Latest Publication Senti Biosciences Inc. has unveiled a groundbreaking logic-gated CAR design that improves targeting of cancer cells while reducing harm to healthy tissues. This advancement aims to enhance the safety and efficacy of CAR T-cell therapies, marking a pivotal moment in cancer treatment. The excitement surrounding this innovation has boosted investor confidence in the biotech company.
March 27, 2026 Senti Biosciences Inc. Reports Financial Results for Q4 and Full Year 2025 Senti Biosciences reported its Q4 and full-year 2025 financial results, showcasing advancements in its clinical pipeline, particularly with SENTI-202 for AML. Despite a decline in cash reserves reflecting R&D investments, the company's strategic focus and positive clinical data position it for future growth.
March 27, 2026 Senti Biosciences Inc. Reports 2025 Annual Financial Results: Strides Amidst Challenges Senti Biosciences reported a net loss of $61.4 million for 2025, driven by rising R&D expenses despite a nominal revenue of $22,000. The company faces liquidity concerns and is pursuing funding to support its innovative therapies amidst operational challenges.
March 23, 2026 Senti Biosciences Inc. to Showcase Groundbreaking Data on SENTI-202 at the Innate Killer Conference Senti Biosciences will present clinical data on SENTI-202, a novel CAR NK cell therapy, at the Innate Killer Conference. The therapy aims to treat relapsed/refractory AML while minimizing harm to healthy cells. The company's innovative approach showcases its commitment to advancing cancer treatment.
March 03, 2026 Senti Biosciences to Showcase Innovations at Upcoming Global Healthcare Conference Senti Biosciences is poised to showcase its Gene Circuit platform at the Leerink Partners 2026 Global Healthcare Conference. CEO Dr. Timothy Lu will discuss advancements aimed at treating incurable diseases, highlighting the potential of engineered Gene Circuits to target cancer cells selectively. The presentation promises insights into the company's future and its strategic role in biotechnology.
February 24, 2026 Senti Biosciences to Showcase Innovations at TD Cowen Health Care Conference Senti Biosciences will present its Gene Circuit technology at the TD Cowen Health Care Conference on March 2, 2026. Dr. Timothy Lu will discuss the company's therapeutic pipeline and strategic priorities, emphasizing collaborative opportunities to advance cancer treatments.
February 20, 2026 Senti Biosciences Inc. Showcases Innovative Gene Circuit Technology at Cell & Gene Live Event Senti Biosciences highlighted its innovative Gene Circuit technology at the Cell & Gene Live event, focusing on their flagship product SENTI-202 for treating hematologic malignancies. With key features like Logic Gating, SENTI-202 aims to effectively target cancer while preserving healthy cells, positioning Senti Bio at the forefront of cell therapy advancements.
February 11, 2026 Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial for SENTI-202 Senti Biosciences has completed enrollment for its Phase 1 clinical trial of SENTI-202, a novel CAR NK cell therapy for relapsed or refractory acute myeloid leukemia. The company plans to engage with the FDA to discuss potential pivotal trials, showcasing promising clinical data and a commitment to innovative therapies.
February 03, 2026 Senti Biosciences Set to Shine at Healthcare Conference Taipei 2026 Senti Biosciences will showcase its Gene Circuit technology at the Healthcare Conference Taipei 2026, emphasizing potential partnerships and advancements in cell therapies. CEO Dr. Timothy Lu leads the presentation, highlighting the company's innovative approach to treating incurable diseases.
January 14, 2026 Senti Biosciences Inc. Showcases Groundbreaking Data at ASH Annual Meeting Senti Biosciences showcased its innovative therapy SENTI-202 for acute myeloid leukemia (AML) at the ASH Annual Meeting 2026. The therapy received FDA RMAT designation, marking a significant achievement in addressing urgent medical needs. Promising clinical trial results highlight the potential effectiveness of their novel Gene Circuit platform.
January 09, 2026 Senti Biosciences Set to Showcase Innovations at Biotech Showcase 2026 Senti Biosciences will present its innovative cell and gene therapies at the Biotech Showcase 2026, highlighting advancements in treatment for complex diseases. CEO Dr. Timothy Lu will lead a panel discussion on the future of biotechnology, emphasizing the company’s proprietary Gene Circuit technology.
December 18, 2025 Senti Biosciences Inc. Announces Employment Inducement Grants Senti Biosciences, Inc. has announced new employment inducement grants to attract top talent, granting stock options to a new employee. This initiative reflects the company's commitment to innovative cell and gene therapies and strategic workforce expansion as it advances its Gene Circuit technology.
December 09, 2025 Senti Biosciences Receives FDA RMAT Designation for SENTI-202: A Game Changer in AML Treatment Senti Biosciences has received FDA RMAT designation for its investigational therapy SENTI-202, aimed at treating relapsed or refractory acute myeloid leukemia. This first-in-class CAR-NK therapy shows promising clinical data and could significantly change treatment outcomes for patients.
December 09, 2025 Senti Biosciences Unveils Promising Clinical Data for SENTI-202 in AML Treatment Senti Biosciences has announced promising results from its Phase 1 trial of SENTI-202, a CAR NK cell therapy for relapsed or refractory AML. The data shows a 50% overall response rate and 42% complete remission, highlighting its potential to improve treatment options for patients with this aggressive disease.
December 04, 2025 Senti Biosciences Inc. to Present SENTI-202 Data at ASH Annual Meeting: Conference Call Scheduled Senti Biosciences will present clinical data for its investigational therapy SENTI-202 at the ASH Annual Meeting on December 9, 2025. This innovative treatment targets AML and MDS using a CAR-NK cell approach. The conference call will feature key executives discussing the therapy's mechanisms and potential impacts on patient care.
November 13, 2025 Senti Biosciences Inc. Reports Third Quarter 2025 Financial Results and Upcoming Clinical Data Presentation Senti Biosciences, Inc. reported its Q3 2025 financial results, revealing significant net losses and cash decline. The company is set to present critical data on its SENTI-202 trial for AML at the ASH Annual Meeting, highlighting its innovative treatment approach.
November 13, 2025 Senti Biosciences Inc. Reports Q3 2025 Financial Results: Navigating Challenges with a Promising Pipeline Senti Biosciences Inc. reports a Q3 2025 net loss of $18.1 million, improving from the previous year. The company navigates challenges with its oncology pipeline, including advancements in SENTI-202 and setbacks with SENTI-301A, while focusing on financial sustainability and governance.
November 03, 2025 Senti Biosciences to Showcase Promising Results of SENTI-202 at ASH Annual Meeting Senti Biosciences will present promising results for its SENTI-202 therapy targeting relapsed/refractory acute myeloid leukemia at the ASH 2025 meeting. Utilizing innovative Logic Gate technology, this therapy aims to selectively eliminate cancer cells while safeguarding healthy tissues. The upcoming presentations signify a potential breakthrough in AML treatment strategies.
October 16, 2025 Senti Biosciences to Showcase Innovative Gene Therapy Platform at Chardan's Conference Senti Biosciences will showcase its innovative Gene Circuit platform at the Chardan Genetic Medicines Conference. CEO Dr. Timothy Lu will highlight advancements in targeted therapies for cancer and other diseases, emphasizing the company's commitment to investor engagement and transparency.
October 06, 2025 Senti Biosciences Set to Showcase Innovations at BioJapan 2025 Senti Biosciences will showcase its innovations at BioJapan 2025, focusing on its Gene Circuit platform for cell and gene therapies. CEO Dr. Timothy Lu will present on October 9, and the company will engage with investors and attendees at its booth.
August 07, 2025 Senti Biosciences Inc. Reports 2025 Q2 Financial Results: A Deep Dive into Progress and Challenges Senti Biosciences recently reported its Q2 2025 financial results, reflecting both significant product development progress and increasing operational challenges. The company faces a net loss of $14.7 million while navigating crucial clinical trials and funding strategies in its pursuit of innovative cancer therapies.
May 06, 2025 Senti Biosciences Inc. Reports Q1 2025 Financial Results: Navigating Challenges Amidst Clinical Advances Senti Biosciences Inc. reported a net loss of $14.1 million for Q1 2025, reflecting increased operational costs and ongoing reliance on external funding. Despite challenges, the company is advancing its clinical pipeline while restructuring leadership and seeking additional financing.
March 20, 2025 Senti Biosciences Inc. Reports 2024 Annual Results: A Year of Strategic Shifts and Clinical Advancements Senti Biosciences Inc. reports a year of strategic advancements in its 2024 annual results, showcasing improved financial metrics and significant progress in clinical trials, particularly for its SENTI-202 candidate. The company continues to face revenue challenges but remains focused on innovative partnerships and future growth in oncology therapies.
March 20, 2025 Senti Biosciences Inc. Reports Financial Results and Progress in Gene Therapy Pipeline Senti Biosciences reported its 2024 financial results, showcasing a strong cash position and advancements in its SENTI-202 gene therapy trial for AML. The initial trial data shows promise, with two patients achieving complete remission. The company is set to continue its growth and innovation in 2025.
March 13, 2025 Senti Biosciences Welcomes Feng Hsiung to Board of Directors Senti Biosciences has appointed Feng Hsiung to its Board of Directors, enhancing its strategic capabilities in developing cell and gene therapies. Hsiung's extensive investment expertise is expected to support the company's growth objectives. Additionally, Senti Bio announced stock options for new employees, reinforcing its commitment to talent acquisition.
February 25, 2025 Senti Biosciences Inc. Expands Leadership Team with Key Appointments Senti Biosciences has appointed Jay Cross as CFO and Faraz Siddiqui as SVP of Technical Operations to strengthen its leadership team. These appointments aim to enhance financial and operational strategies as the company progresses in developing innovative cell and gene therapies.
February 07, 2025 SWOT Analysis of Senti Biosciences Inc. in 2025 This SWOT analysis of Senti Biosciences Inc. in 2025 details the company's strengths in innovative therapies and partnerships, while addressing financial weaknesses and competitive threats. The analysis highlights potential growth opportunities within the biotechnology industry.
November 14, 2024 Senti Biosciences Inc. Reports Q3 2024 Financial Results: A Challenging Quarter with Strategic Developments Senti Biosciences Inc. reported a significant net loss of $28.9 million in Q3 2024, amid ongoing strategic developments and partnerships. The company is refocusing its efforts on clinical programs despite financial pressures, indicating potential for future growth in innovative therapies.
August 13, 2024 Senti Biosciences Inc. Reports Q2 2024 Financial Results: A Mixed Bag Amid Strategic Developments Senti Biosciences Inc. reported no revenue for Q2 2024 but showed improved operational efficiency with reduced losses. The company is focused on advancing its gene therapies and securing future funding amid ongoing challenges.
May 09, 2024 Senti Biosciences Inc. Reports Q1 2024 Financial Results: A Step Towards Recovery Senti Biosciences reports improved Q1 2024 financial results, with a reduced net loss of $12.1 million and strategic partnerships enhancing growth potential. The company's proactive measures signal a promising future in the competitive biotech sector.
March 21, 2024 Senti Biosciences Inc. Reports 2023 Annual Results: A Year of Strategic Transformations Senti Biosciences' 2023 annual report reveals strategic transformations, including asset sales and collaborations aimed at enhancing global reach. Despite financial losses, the company remains committed to advancing its R&D pipeline for oncology therapies.